Bio-Techne Corporation (TECH)

NASDAQ · Health Care · Biotechnology
By Alex · Tickerpine
$72.23
+0.08 (+0.11%)
Price — last 10 years monthly, dividend-adjusted · hover for detail
Market Cap
$11.25B
P/E (TTM)
103.2
Forward P/E
31.3
EPS (TTM)
$0.70
ROE
5.34%
Profit Margin
9.05%
Revenue Growth
-1.50%
Dividend Yield
0.44%
Beta
1.28
52W High
$72.39
52W Low
$43.20
Analyst Target
$69.73

TECH stock forecast: what analysts expect

Consensus rating
Hold
Avg. 12-month target
$69.73
Implied upside
-3.5%

Wall Street analysts covering Bio-Techne Corporation currently rate the stock a Hold on average, with a mean 12-month price target of $69.73 — -3.5% versus the last price of $72.23. Targets reflect analyst opinion, not a guarantee.

What would an investment in TECH be worth today?
Run TECH through our free historical return calculator.
Calculate TECH returns →

TECH historical returns

PeriodTotal returnAnnualized (CAGR)$1,000 grew to
1 year +32.8% +32.8% $1,328
3 years -6.5% -2.2% $935
5 years -40.8% -10.0% $592
10 years +191% +11.3% $2,906
20 years +580% +10.1% $6,805
Since 1989 +79,100% +19.5% $791,996

Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in TECH.

TECH annual returns by year

2026 YTD +23.2%
2025 -17.9%
2024 -6.2%
2023 -6.5%
2022 -35.7%
2021 +63.4%
2020 +45.4%
2019 +52.7%
2018 +12.6%
2017 +27.4%

Congress trading in TECH

2 members of Congress have disclosed trading TECH — 3 purchases and 1 sale worth an estimated $32,000. Most recent disclosure: Dec 5, 2025.

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Company website ↗

TECH Key Statistics

Previous Close$72.15P/E Ratio103.2
Market Cap$11.25BPEG Ratio0.97
Revenue (TTM)$1.21BROE5.34%
Gross Margin66.40%ROA7.45%
Debt / Equity13.9Employees3,100

TECH in plain English

TECH stock: frequently asked questions

What is Bio-Techne Corporation's stock price today?

Bio-Techne Corporation (TECH) last traded at $72.23 on the NASDAQ. Over the past 52 weeks the stock has traded between $43.20 and $72.39.

Is TECH stock a buy or a sell?

Wall Street analysts' consensus rating on TECH is "Hold", with an average 12-month price target of $69.73 — about -3.5% versus the current price of $72.23. Analyst targets are opinions, not guarantees; always do your own research.

How much would $1,000 invested in TECH 10 years ago be worth today?

A $1,000 investment in Bio-Techne Corporation made 10 years ago would be worth about $2,906 today (dividends reinvested) — a total return of 191%, or 11.3% per year.

Does TECH pay a dividend?

Yes. Bio-Techne Corporation currently pays a dividend yielding about 0.44% per year at today's share price.

What is TECH's P/E ratio?

TECH trades at a trailing price-to-earnings ratio of 103.2, and 31.3 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.

Do members of Congress trade TECH stock?

Yes — 2 members of Congress have disclosed trades in TECH under the STOCK Act, totaling 3 purchases and 1 sales worth an estimated $32,000.

What is Bio-Techne Corporation's ticker symbol?

Bio-Techne Corporation trades under the ticker symbol TECH on the NASDAQ.

Compare TECH with peers

TECH vs LLYEli Lilly and Company $1,220.28 TECH vs JNJJohnson & Johnson $260.86 TECH vs ABBVAbbVie Inc. $248.76 TECH vs UNHUnitedHealth Group Incorporated $405.59 TECH vs MRKMerck & Company, Inc. $132.92

Data last refreshed from public sources. Figures may be delayed. Not investment advice.